Skip to main content
SpringerLink
Log in

Heart Failure in Hypertension

Prevention and Treatment

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The heart failure epidemic calls for urgent prevention efforts. Hypertension is present in the majority of individuals who develop heart failure and carries the highest population-attributable risk for heart failure together with coronary heart disease. Therefore, hypertension is a natural prime target for prevention interventions. However, a substantial proportion of heart failure develops among individuals with a systolic BP (SBP) level below current therapeutic target recommendations (140 mmHg or 130 mmHg for high-risk groups), which are accepted as ‘normal’ levels, underlining the importance of prehypertension for heart failure development.

Prevalence and incidence of both hypertension and prehypertension are high. Efforts to prevent or attenuate BP rise could lead to a substantial reduction of complications, including heart failure development. Lifestyle modifications play a crucial role in preventing elevation of BP levels and better control of high BP. Weight loss, control of sodium intake and diet, and physical activity are essential steps towards this direction. However, when medications are needed to reduce BP levels, the selection of the appropriate agent is important not only for effective control of BP but also to reduce hypertension-related complications. Diuretics and renin-angiotensin system modulators seem to be the most effective agents for heart failure prevention according to the existing evidence.

Patients with heart failure and hypertension should be treated for hypertension based on the same principles, although medication selection should take into account concomitant medications, other risk factors and type of heart failure (reduced vs preserved left ventricular ejection fraction).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  2. Robinson SC. Range of normal blood pressure: a statistical and clinical study of 11 383 persons. Arch Intern Med 1939; 64: 409–44

    Article  Google Scholar 

  3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903–13

    Article  PubMed  Google Scholar 

  4. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001 Nov 17; 358 (9294): 1682–6

    Article  PubMed  CAS  Google Scholar 

  5. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002 Feb 27; 287 (8): 1003–10

    Article  PubMed  Google Scholar 

  6. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005 Jul 27; 294 (4): 466–72

    Article  PubMed  CAS  Google Scholar 

  7. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004 Oct 25; 164 (19): 2126–34

    Article  PubMed  Google Scholar 

  8. Ogunniyi MO, Croft JB, Greenlund KJ, et al. Racial/ethnic differences in microalbuminuria among adults with prehypertension and hypertension: National Health and Nutrition Examination Survey (NHANES), 1999-2006. Am J Hypertens 2010 Aug; 23 (8): 859–64

    Article  PubMed  Google Scholar 

  9. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities study. Arch Intern Med 1995 Apr 10; 155 (7): 677–84

    Article  PubMed  CAS  Google Scholar 

  10. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension 2000 Nov; 36 (5): 780–9

    Article  PubMed  CAS  Google Scholar 

  11. Wyatt SB, Akylbekova EL, Wofford MR, et al. Prevalence, awareness, treatment, and control of hypertension in the Jackson Heart Study. Hypertension 2008 Mar; 51 (3): 650–6

    Article  PubMed  CAS  Google Scholar 

  12. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15–21; 365 (9455): 217–23

    PubMed  Google Scholar 

  13. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 May 14; 289 (18): 2363–9

    Article  PubMed  Google Scholar 

  14. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002 Dec; 40 (6): 920–7

    Article  PubMed  CAS  Google Scholar 

  15. Reynolds K, Gu D, Muntner P, et al. Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J Hypertens 2003 Jul; 21 (7): 1273–81

    Article  PubMed  CAS  Google Scholar 

  16. Gupta PC, Gupta R, Pednekar MS. Hypertension prevalence and blood pressure trends in 88 653 subjects in Mumbai, India. J Hum Hypertens 2004 Dec; 18 (12): 907–10

    Article  PubMed  CAS  Google Scholar 

  17. Sekikawa A, Hayakawa T. Prevalence of hypertension, its awareness and control in adult population in Japan. J Hum Hypertens 2004 Dec; 18 (12): 911–2

    Article  PubMed  CAS  Google Scholar 

  18. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007 Jan; 25 (1): 73–9

    Article  PubMed  CAS  Google Scholar 

  19. Meehan KA, Bankoski AJ, Tejan E, et al. Hypertension in Bo, Sierra Leone. Ethn Dis 2011 Spring; 21 (2): 237–42

    PubMed  Google Scholar 

  20. Twagirumukiza M, De Bacquer D, Kips JG, et al. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens 2011 Jul; 29 (7): 1243–52

    Article  PubMed  CAS  Google Scholar 

  21. Steyn K, Bradshaw D, Norman R, et al. Determinants and treatment of hypertension in South Africans: the first Demographic and Health Survey. S Afr Med J 2008 May; 98 (5): 376–80

    PubMed  Google Scholar 

  22. Ibrahim MM. Epidemiology of hypertension in Egypt. Saudi J Kidney Dis Transpl 1999 Jul-Sep; 10 (3): 352–6

    PubMed  CAS  Google Scholar 

  23. Khedda S, Chibane A, Temmar M, et al. Hypertension in Algeria: results of the national survey, 2004 [online]. Available from URL: http://www.ehs-egypt.net/pdf/pan-selim.pdf [Accessed 2012 Oct 2]

  24. Ben Romdhane H, Ben Ali S, Skhiri H, et al. Hypertension among Tunisian adults: results of the TAHINA project. Hypertens Res 2012 Mar; 35 (3): 341–7

    Article  PubMed  Google Scholar 

  25. Rubinstein A, Alcocer L, Chagas A. High blood pressure in Latin America: a call to action. Ther Adv Cardiovasc Dis 2009 Aug; 3 (4): 259–85

    Article  PubMed  Google Scholar 

  26. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995 Jul; 26 (1): 60–9

    Article  PubMed  CAS  Google Scholar 

  27. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008 Nov; 52 (5): 818–27

    Article  PubMed  CAS  Google Scholar 

  28. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics — 2012 update: a report from the American Heart Association. Circulation. Epub 2011 Dec 15

  29. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007 Jul; 55 (7): 1056–65

    Article  PubMed  Google Scholar 

  30. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004 Oct; 44 (4): 398–404

    Article  PubMed  CAS  Google Scholar 

  31. Ahluwalia IB, Mack KA, Murphy W, et al. State-specific prevalence of selected chronic disease-related characteristics: Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003 Aug 22; 52 (8): 1–80

    PubMed  Google Scholar 

  32. Aslam F, Haque A, Agostini JV, et al. Hypertension prevalence and prescribing trends in older US adults: 1999–2004. J Clin Hypertens (Greenwich) 2010 Feb 1; 12 (2): 75–81

    Article  Google Scholar 

  33. Arnett DK, McGovern PG, Jacobs Jr DR, et al. Fifteenyear trends in cardiovascular risk factors (1980–1982 through 1995–1997): the Minnesota Heart Survey. Am J Epidemiol 2002 Nov 15; 156 (10): 929–35

    Article  PubMed  Google Scholar 

  34. Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med 1989 Apr; 149 (4): 780–8

    Article  PubMed  CAS  Google Scholar 

  35. Diez Roux AV, Chambless L, Merkin SS, et al. Socioeconomic disadvantage and change in blood pressure associated with aging. Circulation 2002 Aug 6; 106 (6): 703–10

    Article  PubMed  Google Scholar 

  36. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 1999 Jan; 13 (1): 13–21

    CAS  Google Scholar 

  37. Vargas CM, Ingram DD, Gillum RF. Incidence of hypertension and educational attainment: the NHANES I epidemiologic follow up study. First National Health and Nutrition Examination Survey. Am J Epidemiol 2000 Aug1; 152 (3): 272–8

    CAS  Google Scholar 

  38. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health 1988 Jun; 78 (6): 676–9

    Article  PubMed  CAS  Google Scholar 

  39. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001 Mar; 37 (3): 869–74

    Article  PubMed  CAS  Google Scholar 

  40. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar 6; 103 (9): 1245–9

    Article  PubMed  CAS  Google Scholar 

  41. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 2008 Oct 27; 168 (19): 2138–45

    Article  PubMed  Google Scholar 

  42. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med 2009 Apr 13; 169 (7): 708–15

    Article  PubMed  CAS  Google Scholar 

  43. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008 Apr 1; 101 (7): 1016–22

    Article  PubMed  Google Scholar 

  44. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005 Mar–Apr; 47 (5): 320–32

    Article  PubMed  Google Scholar 

  45. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995 Dec; 26 (7): 1565–74

    Article  PubMed  CAS  Google Scholar 

  46. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004 Feb 4; 43 (3): 317–27

    Article  PubMed  Google Scholar 

  47. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007 Aug 21; 50 (8): 768–77

    Article  PubMed  Google Scholar 

  48. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20; 355 (3): 251–9

    Article  PubMed  CAS  Google Scholar 

  49. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002 Dec; 23 (23): 1867–76

    Article  PubMed  CAS  Google Scholar 

  50. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002 Mar; 87 (3): 235–41

    Article  PubMed  CAS  Google Scholar 

  51. Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?. Mayo Clin Proc 2011 Jun; 86 (6): 531–9

    Article  PubMed  Google Scholar 

  52. Das A, Abraham S, Deswal A. Advances in the treatment of heart failure with a preserved ejection fraction. Curr Opin Cardiol 2008 May; 23 (3): 233–40

    Article  PubMed  Google Scholar 

  53. Shin DD, Brandimarte F, De Luca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007 Jan 22; 99 (2A): 4A–23A

    Article  PubMed  CAS  Google Scholar 

  54. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J 1989 Jul; 10 (7): 647–56

    PubMed  CAS  Google Scholar 

  55. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003 Jan 7; 138 (1): 10–6

    Article  PubMed  Google Scholar 

  56. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996 May 22–29; 275 (20): 1557–62

    Article  PubMed  CAS  Google Scholar 

  57. Aronow WS, Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest 1999 Mar; 115 (3): 867–8

    Article  PubMed  CAS  Google Scholar 

  58. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension 2009 Mar; 53 (3): 458–65

    Article  PubMed  CAS  Google Scholar 

  59. Demirovic J, Prineas R, Rudolph M. Epidemiology of congestive heart failure in three ethnic groups. Congest Heart Fail 2001 Mar–Apr; 7 (2): 93–6

    Article  PubMed  Google Scholar 

  60. Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999 Jun 14; 159 (11): 1197–204

    Article  PubMed  CAS  Google Scholar 

  61. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004 Sep 14; 110 (11): 1424–30

    Article  PubMed  Google Scholar 

  62. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007 Feb 20; 115 (7): 855–60

    Article  PubMed  Google Scholar 

  63. Britton KA, Gaziano JM, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail 2009 Dec; 11 (12): 1129–34

    Article  PubMed  Google Scholar 

  64. Vasan RS, Larson MG, Leip EP, et al. Impact of highnormal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 Nov 1; 345 (18): 1291–7

    Article  PubMed  CAS  Google Scholar 

  65. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011 Aug; 97 (16): 1304–11

    Google Scholar 

  66. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999 Feb 17; 281 (7): 634–9

    Article  PubMed  CAS  Google Scholar 

  67. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the National Heart, Lung, and Blood Institute. Circulation 2009 Jun 23; 119 (24): 3070–7

    Article  PubMed  Google Scholar 

  68. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure prediction in the elderly: the Health ABC heart failure score. Circ Heart Fail 2008 July 1; 1 (2): 125–33

    Article  PubMed  Google Scholar 

  69. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002 Dec 10; 106 (24): 3068–72

    Article  PubMed  Google Scholar 

  70. Georgiopoulou VV, Kalogeropoulos AP, Butler J. Dilemmas of blood pressure management for heart failure prevention. Circ Heart Fail 2011 Jul; 4 (4): 528–33

    Article  PubMed  Google Scholar 

  71. Drukteinis JS, Roman MJ, Fabsitz RR, et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 2007 Jan 16; 115 (2): 221–7

    Article  PubMed  Google Scholar 

  72. Weber KT, Brilla CG, Campbell SE, et al. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992 Aug; 1 (2): 75–85

    Article  PubMed  CAS  Google Scholar 

  73. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996 Sep 9; 156 (16): 1789–96

    Article  PubMed  CAS  Google Scholar 

  74. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987 Jan; 75 (1 Pt 2): I19–25

    PubMed  CAS  Google Scholar 

  75. Brush Jr JE, Cannon 3rd RO, Schenke WH, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988 Nov 17; 319 (20): 1302–7

    Article  PubMed  Google Scholar 

  76. Nolan SE, Mannisi JA, Bush DE, et al. Increased afterload aggravates infarct expansion after acute myocardial infarction. J Am Coll Cardiol 1988 Nov; 12 (5): 1318–25

    Article  PubMed  CAS  Google Scholar 

  77. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure: treatment strategies. Heart Fail Rev 2008 Sep; 13 (3): 367–75

    Article  PubMed  CAS  Google Scholar 

  78. Wright JW, Harding JW. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol 2004 Mar; 72 (4): 263–93

    Article  PubMed  CAS  Google Scholar 

  79. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 Sep 20; 112 (12): e154–235

    Article  PubMed  Google Scholar 

  80. Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of ‘asymptomatic’ left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003 Jun 3; 138 (11): 907–16

    Article  PubMed  Google Scholar 

  81. Davies M, Hobbs F, Davis R, et al. Prevalence of leftventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001 Aug 11; 358 (9280): 439–44

    Article  PubMed  CAS  Google Scholar 

  82. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003 Jan 8; 289 (2): 194–202

    Article  PubMed  Google Scholar 

  83. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997 Sep 20; 350 (9081): 829–33

    Article  PubMed  CAS  Google Scholar 

  84. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003 Aug 26; 108 (8): 977–82

    Article  PubMed  Google Scholar 

  85. Verdecchia P, Angeli F, Gattobigio R, et al. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 2005 Mar; 45 (3): 412–8

    Article  PubMed  CAS  Google Scholar 

  86. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992 Sep 3; 327 (10): 669–77

    Article  CAS  Google Scholar 

  87. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandola-pril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21; 333 (25): 1670–6

    CAS  Google Scholar 

  88. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003 May 31; 361 (9372): 1843–8

    Article  PubMed  CAS  Google Scholar 

  89. Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in Black and White patients. J Am Coll Cardiol 2002 Jul 17; 40 (2): 311–7

    Article  PubMed  CAS  Google Scholar 

  90. Exner DV, Dries DL, Waclawiw MA, et al. Betaadrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999 Mar 15; 33 (4): 916–23

    Article  PubMed  CAS  Google Scholar 

  91. No authors listed. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997 Feb 8; 349 (9049): 375-80

  92. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. J Am Coll Cardiol 1997 Feb; 29 (2): 229–36

    Article  CAS  Google Scholar 

  93. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo substudy. Circulation 2004 Jan 20; 109 (2): 201–6

    Article  PubMed  CAS  Google Scholar 

  94. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001 Dec 1; 88 (11): 1298–300

    Article  PubMed  CAS  Google Scholar 

  95. Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999 Jun; 106 (6): 605–12

    Article  PubMed  CAS  Google Scholar 

  96. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000 May; 35 (6): 1628–37

    Article  PubMed  CAS  Google Scholar 

  97. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001 Apr 9; 161 (7): 996–1002

    Article  PubMed  CAS  Google Scholar 

  98. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001 Mar; 249 (3): 253–61

    Article  PubMed  CAS  Google Scholar 

  99. Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005 Dec 1; 96 (11): 1530–6

    Article  PubMed  Google Scholar 

  100. Kalogeropoulos A, Psaty BM, Vasan RS, et al. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail 2010 Jul; 3 (4): 495–502

    Article  PubMed  Google Scholar 

  101. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005 Jan 29–Feb 4; 365 (9457): 434–41

    PubMed  CAS  Google Scholar 

  102. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986 Nov 28; 256 (20): 2823–8

    Article  PubMed  CAS  Google Scholar 

  103. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986 Oct 25; 2 (8513): 933–6

    Article  PubMed  CAS  Google Scholar 

  104. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest: the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003 Jul; 24 (13): 1204–9

    Article  Google Scholar 

  105. Myerburg RJ, Mitrani R, Interian Jr A, et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998 Apr 21; 97 (15): 1514–21

    Article  PubMed  CAS  Google Scholar 

  106. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227–39

    Article  PubMed  Google Scholar 

  107. Ferrucci L, Furberg CD, Penninx BW, et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001 Oct 16; 104 (16): 1923–6

    Article  PubMed  CAS  Google Scholar 

  108. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486–97

    Article  Google Scholar 

  109. Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005 Sep; 7 (9): 505–12

    Article  Google Scholar 

  110. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105–87

    Article  PubMed  CAS  Google Scholar 

  111. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 May 12; 97 (18): 1837–47

    Article  PubMed  CAS  Google Scholar 

  112. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002 Oct 16; 288 (15): 1882–8

    Article  PubMed  Google Scholar 

  113. Falkner B, Gidding SS, Portman R, et al. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008 Aug; 122 (2): 238–42

    Article  PubMed  Google Scholar 

  114. Geleijnse JM, Kok FJ, Grobbee DE. Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations. Eur J Public Health 2004 Sep; 14 (3): 235–9

    Article  PubMed  Google Scholar 

  115. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003 Nov; 42 (5): 878–84

    Article  PubMed  CAS  Google Scholar 

  116. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001 Jan 2; 134 (1): 1–11

    Article  PubMed  CAS  Google Scholar 

  117. Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984 Jul 27; 252 (4): 487–90

    Article  PubMed  CAS  Google Scholar 

  118. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 1997 Apr 17; 336 (16): 1117–24

    Article  PubMed  CAS  Google Scholar 

  119. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001 Jan 4; 344 (1): 3–10

    CAS  Google Scholar 

  120. No authors listed. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997 Mar 24; 157 (6): 657-67

  121. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001 Mar 12; 161 (5): 685–93

    Article  PubMed  CAS  Google Scholar 

  122. Frohlich ED, Chien Y, Sesoko S, et al. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol 1993 Jan; 264 (1 Pt 2): R30–4

    PubMed  CAS  Google Scholar 

  123. de Simone G, Devereux RB, Camargo MJ, et al. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993 Jun; 264 (6 Pt 2): H2103–10

    PubMed  Google Scholar 

  124. de Simone G, Devereux RB, Camargo MJ, et al. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996 Mar; 9 (3): 216–22

    Article  PubMed  Google Scholar 

  125. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003 Apr 23–30; 289 (16): 2083–93

    Article  PubMed  Google Scholar 

  126. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE). TONE Collaborative Research Group. JAMA 1998 Mar 18; 279 (11): 839–46

    CAS  Google Scholar 

  127. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006 Apr 4; 144 (7): 485–95

    Article  PubMed  Google Scholar 

  128. Hyman DJ, Pavlik VN, Taylor WC, et al. Simultaneous vs sequential counseling for multiple behavior change. Arch Intern Med 2007 Jun 11; 167 (11): 1152–8

    Article  PubMed  Google Scholar 

  129. Frisoli TM, Schmieder RE, Grodzicki T, et al. Beyond salt: lifestyle modifications and blood pressure. Eur Heart J 2011 Dec; 32 (24): 3081–7

    Article  PubMed  Google Scholar 

  130. Fuchs FD. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther 2010 Dec; 28 (6): 339–43

    Article  PubMed  Google Scholar 

  131. Chobanian AV. Prehypertension revisited. Hypertension 2006 Nov; 48 (5): 812–4

    Article  PubMed  CAS  Google Scholar 

  132. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006 Apr 20; 354 (16): 1685–97

    Article  PubMed  CAS  Google Scholar 

  133. Luders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008 Jul; 26 (7): 1487–96

    Article  PubMed  CAS  Google Scholar 

  134. Skov K, Eiskjaer H, Hansen HE, et al. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007 Jul; 50 (1): 89–95

    Article  PubMed  CAS  Google Scholar 

  135. No authors listed. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg. JAMA 1970 Aug 17; 213 (7): 1143-52

  136. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997 Jul 16; 278 (3): 212–6

    CAS  Google Scholar 

  137. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145–53

    CAS  Google Scholar 

  138. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 May 1; 358 (18): 1887–98

    Article  PubMed  CAS  Google Scholar 

  139. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993 Mar 8; 153 (5): 578–81

    Article  PubMed  CAS  Google Scholar 

  140. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996 Apr; 27 (5): 1214–8

    Article  PubMed  CAS  Google Scholar 

  141. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009 Mar; 30 (6): 679–88

    Article  PubMed  CAS  Google Scholar 

  142. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009 Aug 15; 374 (9689): 525–33

    Article  PubMed  Google Scholar 

  143. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29; 362 (17): 1575–85

    Article  PubMed  CAS  Google Scholar 

  144. No authors listed. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160): 703-13

  145. McNair A, Rasmussen S, Nielsen PE, et al. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate. Acta Med Scand 1980; 207 (5): 413–6

    PubMed  CAS  Google Scholar 

  146. Wilner KD, Ziegler MG. Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension. Am J Cardiol 1987 May 29; 59 (14): 82G–6G

    Article  PubMed  CAS  Google Scholar 

  147. Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006 May 9; 113 (18): 2201–10

    Article  PubMed  CAS  Google Scholar 

  148. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757–64

    Article  CAS  Google Scholar 

  149. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998 Dec; 16 (12 Pt 1): 1823–9

    Article  PubMed  CAS  Google Scholar 

  150. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861–9

    Article  PubMed  CAS  Google Scholar 

  151. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005 Dec; 23 (12): 2157–72

    Article  PubMed  CAS  Google Scholar 

  152. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372 (9644): 1174–83

    Article  PubMed  CAS  Google Scholar 

  153. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011 Mar 14; 171 (5): 384–94

    Article  PubMed  Google Scholar 

  154. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999 Nov 20; 354 (9192): 1751–6

    CAS  Google Scholar 

  155. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000 Jul 29; 356 (9227): 366–72

    Article  PubMed  CAS  Google Scholar 

  156. No authors listed. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000 Apr 19; 283 (15): 1967-75

  157. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981–97

    Google Scholar 

  158. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003 Apr 23-30; 289 (16): 2073–82

    Article  PubMed  CAS  Google Scholar 

  159. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb 13; 348 (7): 583–92

    Article  PubMed  CAS  Google Scholar 

  160. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995 Feb 1; 91 (3): 698–706

    Article  PubMed  CAS  Google Scholar 

  161. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000 Oct; 18 (10): 1465–75

    Article  PubMed  CAS  Google Scholar 

  162. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of singledrug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997 Apr 15; 95 (8): 2007–14

    CAS  Google Scholar 

  163. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011 Apr; 57 (4): 689–94

    Article  PubMed  CAS  Google Scholar 

  164. Leren P, Helgeland A. Oslo Hypertension Study. Drugs 1986; 31 Suppl. 1: 41–5

    Article  PubMed  Google Scholar 

  165. No authors listed. The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1980 Jun 14; 1 (8181): 1261-7

  166. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359 (23): 2417–28

    Article  PubMed  CAS  Google Scholar 

  167. Ernst ME, Neaton JD, Grimm Jr RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 2011 Dec; 58 (6): 1001–7

    Article  PubMed  CAS  Google Scholar 

  168. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004 Jan; 43 (1): 4–9

    Article  PubMed  CAS  Google Scholar 

  169. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010 Sep; 56 (3): 463–70

    Article  PubMed  CAS  Google Scholar 

  170. Klingbeil AU, Schneider M, Martus P, et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul; 115 (1): 41–6

    Article  PubMed  Google Scholar 

  171. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a metaanalysis of randomized double-blind studies. JAMA 1996 May 15; 275 (19): 1507–13

    Article  PubMed  CAS  Google Scholar 

  172. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009 Nov; 54 (5): 1084–91

    Article  PubMed  CAS  Google Scholar 

  173. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001 Jun; 19 (6): 1167–76

    Article  PubMed  CAS  Google Scholar 

  174. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995–1003

    Article  PubMed  CAS  Google Scholar 

  175. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002 Nov; 20 (11): 2293–300

    Article  PubMed  CAS  Google Scholar 

  176. Barrios V, Escobar C, Calderon A, et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006 Dec; 7 (4): 236–42

    Article  CAS  Google Scholar 

  177. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002 Jan 24; 89 (2A): 18A-25A; discussion A-6A

  178. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547–59

    Article  PubMed  CAS  Google Scholar 

  179. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009 Oct 6; 120 (14): 1380–9

    Article  PubMed  CAS  Google Scholar 

  180. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527–35

    Article  PubMed  CAS  Google Scholar 

  181. Angeli F, Verdecchia P, Reboldi GP, et al. Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol 2004 Jan 15; 93 (2): 240–3

    Article  PubMed  CAS  Google Scholar 

  182. Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: still a HOPE for ACE inhibitors?. Expert Opin Pharmacother 2011 Apr; 12 (6): 839–43

    Article  PubMed  CAS  Google Scholar 

  183. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004 Nov 11; 351 (20): 2058–68

    Article  PubMed  CAS  Google Scholar 

  184. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54: 227–41

    Article  PubMed  CAS  Google Scholar 

  185. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119 (4): 530–7

    Article  PubMed  CAS  Google Scholar 

  186. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011 May; 32 (10): 1227–34

    Article  PubMed  CAS  Google Scholar 

  187. Novartis Pharmaceuticals Corporation. Important drug warning. 2012 [online]. Available from URL: http://www.pharma.us.novartis.com/assets/pdf/Tekturna_Quo_Site_for_Professionals.pdf [Accessed 2012 Feb 20]

  188. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct 29-Nov 4; 366 (9496): 1545–53

    Article  PubMed  CAS  Google Scholar 

  189. Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007 Aug 14; 50 (7): 563–72

    Article  PubMed  CAS  Google Scholar 

  190. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665

  191. Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008 Sep 23; 52 (13): 1062–72

    Article  PubMed  CAS  Google Scholar 

  192. Caglar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011 Dec; 15 (12): 1359–68

    PubMed  CAS  Google Scholar 

  193. Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; (8): CD003654

  194. Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010 Mar 13; 375 (9718): 906–15

    Article  PubMed  CAS  Google Scholar 

  195. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011 Mar 2; 305 (9): 913–22

    Article  PubMed  CAS  Google Scholar 

  196. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006 Jul 20; 355 (3): 260–9

    Article  PubMed  CAS  Google Scholar 

  197. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008 Feb; 29 (3): 339–47

    Article  PubMed  Google Scholar 

  198. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004 Jul; 25 (14): 1214–20

    Article  PubMed  CAS  Google Scholar 

  199. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010 Feb 9; 55 (6): 526–37

    Article  PubMed  Google Scholar 

  200. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995 Oct; 13 (10): 1091–5

    Article  PubMed  CAS  Google Scholar 

  201. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998 Nov; 11 (11 Pt 1): 1394–404

    Article  PubMed  CAS  Google Scholar 

  202. No authors listed. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun 4; 316 (23): 1429-35

    Google Scholar 

  203. No authors listed. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991 Aug 1; 325 (5): 293-302

    Google Scholar 

  204. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002 Oct 16; 40 (8): 1414–21

    Article  PubMed  CAS  Google Scholar 

  205. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003 Sep 6; 362 (9386): 772–6

    Article  PubMed  CAS  Google Scholar 

  206. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angioten-sin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003 Sep 6; 362 (9386): 767–71

    Article  PubMed  CAS  Google Scholar 

  207. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec 6; 345 (23): 1667–75

    Article  PubMed  CAS  Google Scholar 

  208. Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE 2010; 5 (4): e9946

  209. Mehta PA, McDonagh S, Phillips J, et al. Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect?. Clin Cardiol 2009 Sep; 32 (9): 513–8

    Article  PubMed  CAS  Google Scholar 

  210. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008 May; 1 (1): 17–24

    Article  PubMed  CAS  Google Scholar 

  211. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart fail-uRE (ATMOSPHERE) study. Eur J Heart Fail 2011 Jan; 13 (1): 107–14

    Article  PubMed  CAS  Google Scholar 

  212. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011 Jan; 13 (1): 100–6

    Article  PubMed  CAS  Google Scholar 

  213. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996 May 23; 334 (21): 1349–55

    CAS  Google Scholar 

  214. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001 Apr 3; 134 (7): 550–60

    Article  PubMed  CAS  Google Scholar 

  215. No authors listed. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996 Oct 15; 78 (8): 902-7

  216. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005 Aug 2; 46 (3): 425–31

    Article  PubMed  CAS  Google Scholar 

  217. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007 Jan 2; 49 (1): 32–9

    Article  PubMed  CAS  Google Scholar 

  218. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006 Jun 15; 97 (12): 1759–64

    Article  PubMed  CAS  Google Scholar 

  219. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007 Oct; 9 (10): 1064–9

    Article  PubMed  CAS  Google Scholar 

  220. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006 Jun; 27 (12): 1431–9

    Article  PubMed  Google Scholar 

  221. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012 Feb 15; 2: CD003838

  222. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001 Nov; 111 (7): 513–20

    Article  PubMed  CAS  Google Scholar 

  223. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002 Aug; 4 (4): 507–13

    Article  PubMed  CAS  Google Scholar 

  224. Muller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV: efficacy and quality of life. Eur J Heart Fail 2003 Dec; 5 (6): 793–801

    CAS  Google Scholar 

  225. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987 Jun; 75 (6 Pt 2): V56–64

    PubMed  CAS  Google Scholar 

  226. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998; 89 Suppl. 1: 38–46

    Article  PubMed  CAS  Google Scholar 

  227. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010 Jun; 16 (6): e1–194

    Article  PubMed  Google Scholar 

  228. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensinconverting enzyme inhibitor ramipril. Circulation 2001 Oct 2; 104 (14): 1615–21

    Article  PubMed  CAS  Google Scholar 

  229. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4; 359 (23): 2456–67

    Article  PubMed  CAS  Google Scholar 

  230. Fu M, Zhou J, Sun A, et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies. Int J Cardiol 2012 Feb 23; 155 (1): 33–8

    Article  PubMed  Google Scholar 

  231. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004 Aug 3; 110 (5): 558–65

    Article  PubMed  CAS  Google Scholar 

  232. Treatment Of Preserved Cardiac function heart failure with Aldosterone anTagonist (TOPCAT) [online]. Available from URL: http://www.topcatstudy.com/index.asp [Accessed 2011 Nov30]

  233. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009 Jan 13; 53 (2): 184–92

    Article  PubMed  CAS  Google Scholar 

  234. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004 Jun; 6 (4): 453–61

    Article  PubMed  CAS  Google Scholar 

  235. Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000 Apr; 139 (4): 596–608

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Emory Clinical Cardiovascular Research Institute, Emory University, 1462 Clifton Road NE, Suite 535A, Atlanta, GA, 30322, USA

    Vasiliki V. Georgiopoulou, Andreas P. Kalogeropoulos & Javed Butler

Authors
  1. Vasiliki V. Georgiopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas P. Kalogeropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasiliki V. Georgiopoulou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Georgiopoulou, V.V., Kalogeropoulos, A.P. & Butler, J. Heart Failure in Hypertension. Drugs 72, 1373–1398 (2012). https://doi.org/10.2165/11631100-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11631100-000000000-00000

Keywords

Search

Navigation